Janssen Inc. - Articles and news items

Treating multiple myeloma: An interview with Janssen

Blog, Z Homepage promo / 17 May 2017 / Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA

We caught up with Janssen’s Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma…

EC extends approval for Janssen’s daratumumab to include multiple myeloma patients

Industry news / 3 May 2017 / Niamh Marriott, Junior Editor

The EC has granted approval to Janssen Daralex (daratumumab) for use in combination, for the treatment of adult patients with multiple myeloma (MM)…

ustekinumab

NICE recommends Janssen’s Crohn’s Disease biological therapy

Industry news / 2 May 2017 / Niamh Marriott, Junior Editor

NICE has recommended Stelara (ustekinumab) in its final appraisal determination as a treatment option for adult patients with Crohn’s disease…

multiple myeloma

NICE does not recommend Janssen’s multiple myeloma drug

Industry news / 29 March 2017 / Niamh Marriott, Junior Editor

NICE) has published new draft guidance not recommending daratumumab monotherapy (Darzalex, Janssen) to treat some people with multiple myeloma…

REVLIMID

Janssen’s monoclonal antibody receives positive CHMP opinion to treat multiple myeloma

Industry news / 28 February 2017 / Niamh Marriott, Digital Editor

If approved by the European Commission, daratumumab can be used for the treatment of adult patients with multiple myeloma…

Amorsa to collaborate with J&J on treatment-resistant depression therapy

Industry news / 5 January 2017 / Niamh Marriott, Digital Editor

Amorsa has announced a research, option and license agreement with Janssen to develop and commercialise a novel small molecule drug candidate for depression…

guselkumab

EMA to review Janssen’s plaque psoriasis monoclonal antibody

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

Guselkumab is a human monoclonal antibody that targets the protein interleukin (IL)-23, which has been shown to play a key role in the development…

Price drop means leukaemia CDF drug will be routinely available

Industry news / 2 December 2016 / Niamh Louise Marriott, Digital Editor

Ibrutinib had only previously been available through the CDF. Following a reduction in its price for the NHS, it is now recommended in further guidance…

NICE does not recommend Janssen’s Waldenstrom’s macroglobulinaemia candidate

Industry news / 17 October 2016 / Niamh Louise Marriott, Digital Content Producer

NICE has published draft guidance that does not recommend Janssen’s Imbruvica (ibrutinib) for treating some people with Waldenstrom’s macroglobulinaemia…

Janssen submits EU application for rheumatoid arthritis drug

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis…

FDA grants breakthrough therapy designation for depression drug

Industry news / 16 August 2016 / Janssen

Following succesful phase II trials, the FDA have granted a Breakthrough Therapy Designation for esketamine, an investigational antidepressant medication…

Sirukumab meets both co-primary endpoints in rheumatoid arthritis study

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+